<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1310246033
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Saventi
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SACUBITRIL,VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        24,26
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        401.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saventi is a medicine containing an angiotensin receptor neprilysin inhibitor. It delivers two active substances, sacubitril and valsartan.</p><p>Saventi is used to treat a type of long-term heart failure in adults.</p><p>This type of heart failure occurs when the heart is weak and cannot pump enough blood to the lungs and the rest of the body. The most common symptoms of heart failure are breathlessness, fatigue, tiredness and ankle swelling.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Saventi </strong></p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you are allergic to sacubitril, valsartan or any of the other ingredients of this medicine (listed</p><p>in section 6).</p><p style="margin-left:5.75pt; margin-right:24.4pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you are taking another type of medicine called an angiotensin converting enzyme (ACE) inhibitor (for example enalapril, lisinopril or ramipril). ACE inhibitors are used to treat high blood pressure or heart failure. If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Saventi (see &ldquo;Other medicines and Saventi&rdquo;).</p><p style="margin-left:5.75pt; margin-right:24.5pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you or a member of your family have ever had a reaction called angioedema (swelling of the face, lips, tongue and/or throat, difficulties in breathing) when taking an ACE inhibitor or an angiotensin receptor blocker (ARB) (such as valsartan, telmisartan or irbesartan).</p><p style="margin-left:5.75pt; margin-right:15.35pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you have diabetes or impaired kidney function and you are being treated with a blood pressure lowering medicine containing aliskiren (see &ldquo;Other medicines and Saventi &rdquo;).</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you have severe liver disease.</p><p style="margin-left:5.75pt; margin-right:63.7pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you are more than 3 months pregnant (it is also better to avoid this medicine in early pregnancy, see &ldquo;Pregnancy and breast-feeding&rdquo;).</p><p><strong>If any of the above applies to you, do not take Saventi and talk to your doctor. </strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before or when taking Saventi:</p><p style="margin-left:5.75pt; margin-right:10.0pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you are being treated with an angiotensin receptor blocker (ARB) or aliskiren (see &ldquo;Do not take Saventi&rdquo;).</p><p style="margin-left:5.75pt; margin-right:45.0pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you have ever had angioedema (see &ldquo;Do not take Saventi&rdquo; and section 4 &ldquo;Possible side effects&rdquo;).</p><p style="margin-left:5.75pt; margin-right:31.6pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you have low blood pressure or are taking any other medicines that reduce your blood pressure (for example, a diuretic) or are suffering from vomiting or diarrhoea, especially if you are aged 65 years or more, or if you have kidney disease and low blood pressure.</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you have severe kidney disease.</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you are suffering from dehydration.</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if your kidney artery has narrowed.</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you have liver disease.</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->if you experience hallucinations, paranoia or changes in sleeping pattern.</p><p>Your doctor may check the amount of potassium in your blood at regular intervals during Saventi treatment.</p><p><strong>If any of the above applies to you, tell your doctor, pharmacist, or nurse before you take Saventi.</strong></p><p style="margin-left:5.75pt"><strong>Children and adolescents</strong></p><p style="margin-left:5.75pt; margin-right:7.3pt">Do not give this medicine to children (aged below 18 years) because it has not been studied in this age group.</p><p><strong>Other medicines and Saventi </strong></p><p style="margin-left:5.75pt; margin-right:11.45pt; text-align:justify">Tell your doctor, pharmacist, or nurse if you are taking, have recently taken or might take any other medicines. It may be necessary to change the dose, to take other precautions, or even to stop taking one of the medicines. This is particularly important for the following medicines:</p><p style="text-align:justify"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->ACE inhibitors. Do not take Saventi with ACE inhibitors. If you have been taking an ACE inhibitor, wait 36 hours after taking the last dose of the ACE inhibitor before starting to take Saventi (see &ldquo;Do not take Saventi&rdquo;). If you stop taking Saventi, wait 36 hours after taking your last dose of Saventi before starting an ACE inhibitor.</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->other medicines used to treat heart failure or lower blood pressure, such as angiotensin receptor</p><p>blockers or aliskiren (see &ldquo;Do not take Saventi&rdquo;).</p><p style="margin-left:5.75pt; margin-right:37.95pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->some medicines known as statins that are used to lower high cholesterol levels (for example atorvastatin).</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->sildenafil, a medicine used to treat erectile dysfunction or lung hypertension.</p><p style="margin-left:5.75pt; margin-right:37.65pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->medicines that increase the amount of potassium in the blood. These include potassium supplements, salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p style="margin-left:5.75pt; margin-right:11.15pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->painkillers of the type called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 (Cox-2) inhibitors. If you are taking one of these, your doctor may want to check your kidney function when starting or adjusting treatment (see &ldquo;Warnings and precautions&rdquo;).</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->lithium, a medicine used to treat some types of psychiatric illness.</p><p style="margin-left:5.75pt; margin-right:18.85pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->furosemide, a medicine belonging to the type known as diuretics, which are used to increase the amount of urine you produce.</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->nitroglycerine, a medicine used to treat angina pectoris.</p><p style="margin-left:5.75pt; margin-right:11.8pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->some types of antibiotics (rifamycin group), ciclosporin (used to prevent rejection of transplanted organs) or antivirals such as ritonavir (used to treat HIV/AIDS).</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->metformin, a medicine used to treat diabetes.</p><p><strong>If any of the above applies to you, tell your doctor or pharmacist before you take Saventi. </strong></p><p><strong>Pregnancy and breastfeeding</strong></p><p><u>Pregnancy</u></p><p style="margin-left:5.75pt; margin-right:7.3pt">You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking this medicine before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Saventi.</p><p>This medicine is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of<br />pregnancy.</p><p><u>Breast-feeding<br /><!--[if !supportLineBreakNewLine]--></u>Saventi is not recommended for mothers who are breast-feeding. Tell your doctor if you are breastfeeding or about to start breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Saventi affects you. If you feel dizzy or very tired while taking this medicine, do not drive a vehicle, cycle, or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:5.75pt; margin-right:34.05pt">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p style="margin-right:7.3pt">You will usually start by taking 24 mg/26 mg or 49 mg/51 mg twice a day (one tablet in the morning and one tablet in the evening). Your doctor will decide your exact starting dose based on which medicines you have been taking previously. Your doctor will then adjust the dose depending on how you respond to the treatment until the best dose for you is found.</p><p style="margin-right:10.4pt">The usual recommended target dose is 97 mg/103 mg twice a day (one tablet in the morning and one tablet in the evening).</p><p style="margin-right:7.3pt">Patients taking Saventi can develop low blood pressure (dizziness, light-headedness), a high level of potassium in the blood (which would be detected when your doctor performed a blood test) or decreased kidney function. If this happens, your doctor may reduce the dose of any other medicine you are taking, temporarily reduce your Saventi dose or stop your Saventi treatment completely.</p><p style="margin-right:7.3pt">Swallow the tablets with a glass of water. You can take Saventi with or without food. Splitting or crushing of the tablets is not recommended.</p><p><strong>If you take more Saventi than you should</strong></p><p>If you have accidentally taken too many Saventi, or if someone else has taken your tablets, contact your doctor immediately. If you experience severe dizziness and/or fainting, tell your doctor as quickly as possible and lie down.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p><strong>If you forget to take Saventi</strong></p><p style="margin-left:5.75pt; margin-right:7.3pt">It is advisable to take your medicine at the same time each day. However, if you forget to take a dose, you should simply take the next one at the scheduled time. Do not take a double dose to make up for a forgotten tablet.</p><p style="margin-left:5.75pt; margin-right:7.3pt">&nbsp;</p><p><strong>If you stop taking Saventi</strong></p><p style="margin-left:5.75pt; margin-right:106.1pt">Stopping your treatment with Saventi may cause your condition to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist</p><p style="margin-left:0cm">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Some side effects may be serious.</strong></p><p style="margin-left:5.75pt; margin-right:24.8pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Stop taking Saventi &nbsp;and seek immediate medical attention if you notice any swelling of the face, lips, tongue and/or throat, which may cause difficulties in breathing or swallowing. These may be signs of angioedema (an uncommon side effect which may affect up to 1 in 100 people).</p><p style="margin-left:5.75pt; margin-right:24.8pt; text-indent:0cm"><strong>Other possible side effects:</strong></p><p>If any of the side effects listed below becomes severe, tell your doctor or pharmacist.</p><p>&nbsp;</p><p style="margin-left:5.75pt; margin-right:0cm"><strong><u>Very common </u></strong><u>(may affect more than 1 in 10 people)</u></p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->low blood pressure (dizziness, light-headedness)</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->high level of potassium in the blood (shown in a blood test)</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->decreased renal function (renal impairment)</p><p><strong><u>Common </u></strong><u>(may affect up to 1 in 10 people)</u></p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->cough</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->dizziness</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->diarrhea</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->low level of red blood cells (shown in a blood test)</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->tiredness</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->(acute) renal failure (severe kidney disorder)</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->low level of potassium in the blood (shown in a blood test)</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->headache</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->fainting</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->weakness</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->feeling sick (nausea)</p><p style="margin-left:5.75pt; margin-right:55.3pt; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->low blood pressure (dizziness, light-headedness) when switching from sitting or lying to standing position</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->gastritis (stomach pain, nausea)</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->spinning sensation</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->low level of sugar in the blood (shown in a blood test)</p><p style="margin-left:5.75pt; margin-right:0cm"><strong><u>Uncommon </u></strong><u>(may affect up to 1 in 100 people)</u></p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->allergic reaction with rash and itching</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->dizziness when switching from sitting to standing position</p><p style="text-indent:0cm"><strong><u>Rare</u></strong><u> </u><u>(may affect up to 1 in 1,000 people)</u></p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->hallucinations</p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->changes in sleeping pattern</p><p style="text-indent:0cm"><strong><u>Very rare</u></strong><u><strong> </strong>(may affect up to 1 in 10,000 people)</u></p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->paranoia</p><p style="margin-left:0cm">&nbsp;</p><p style="margin-left:0cm"><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your &lt;doctor, health care provider&gt; &lt;or&gt; &lt;pharmacist&gt;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p style="margin-left:5.75pt; margin-right:7.3pt">Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p style="margin-left:5.75pt; margin-right:7.3pt">Do not Store above 30&deg;C&nbsp;</p><p style="margin-right:106.1pt">This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.</p><p style="margin-left:5.75pt; margin-right:34.05pt">Do not use this medicine if you notice that the pack is damaged or shows signs of tampering. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Saventi film-coated tablets contains</strong></p><p><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->The active substance is sacubitril and valsartan.<br /><!--[if !supportLineBreakNewLine]--><br /><u>Saventi Tablets 24 mg/ 26 mg</u></p><p style="margin-left:5.75pt; margin-right:47.5pt">Each film Coated tablet Contains Sacubitril 24 mg and Valsartan 26 mg<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="margin-right:258.95pt"><u>Saventi Tablets 49 mg/ 51 mg</u></p><p style="margin-right:124.0pt">Each film Coated tablet Contains Sacubitril 49 mg and Valsartan 51 mg</p><p style="margin-left:0cm; margin-right:257.1pt"><u>&nbsp;</u></p><p style="margin-left:5.75pt; margin-right:257.1pt"><u>Saventi Tablets 97 mg/ 103 mg</u></p><p style="margin-left:5.75pt; margin-right:25.0pt">Each film Coated tablet Contains Sacubitril 97 mg and Valsartan 103 mg</p><p>&nbsp;</p><p><strong><u>Other Ingredients:</u></strong></p><p style="margin-left:5.75pt; margin-right:0cm"><strong><u>Tablet</u></strong><strong><u> </u></strong><strong><u>core</u></strong></p><p style="margin-left:5.75pt; margin-right:7.3pt">Microcrystalline cellulose (PH 112), Crospovidone, Croscarmellose sodium,Colloidal silicon Dioxide, Talc, Magnesium stearate, Purified water.</p><p style="margin-left:5.75pt"><strong><u>Coating:</u></strong></p><p style="margin-left:5.75pt; margin-right:146.05pt"><em>Saventi Tablets</em><em> </em><em>24</em><em> </em><em>mg/</em><em> </em><em>26</em><em> </em><em>mg</em><em>:</em><em> </em>Opadry Purple 03F500057 <em>Saventi Tablets</em><em> </em><em>49</em><em> </em><em>mg/51</em><em> </em><em>mg:</em><em> </em>Opadry Yellow 03F520058 <em>Saventi Tablets</em><em> </em><em>97</em><em> </em><em>mg/103</em><em> </em><em>mg: </em>Opadry Pink 03F540048 and Purified water.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Film-coated tablet Pack:
60's, 180's HDPE container pack. 10's Blister Pack
Note: Not all pack sizes may be marketed


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:#ededed; border-color:black; height:19.1pt; width:240.9pt"><p><strong>Marketing Authorization Holder</strong></p></td><td style="background-color:#ededed; border-color:black; height:19.1pt; width:241.0pt"><p><strong>Manufacturer</strong></p></td></tr><tr><td style="border-color:black; height:122.55pt; vertical-align:top; width:240.9pt"><p style="margin-left:0cm; margin-right:0cm"><strong>Sudair Pharma Company (SPC)</strong> &nbsp;</p><p style="margin-left:6.0pt; margin-right:0cm">King Fahad Road &ndash; King Fahad District, Building no. 7639 P.O. Box 12262 Riyadh, Saudi Arabia &nbsp;</p><p style="margin-left:6.0pt; margin-right:0cm">Tel: +966-11-920001432 &nbsp;</p><p style="margin-left:6.0pt; margin-right:0cm">Fax: +966-11-4668195 &nbsp;</p><p style="margin-left:0cm; margin-right:0cm">Email: info@sudairpharma.com </p></td><td style="height:122.55pt; vertical-align:top; width:241.0pt"><p><strong>MSN Laboratories Private Limited</strong>Formulations Division, Unit-II,</p><p>Sy. No. 1277 &amp; 1319 to 1324,</p><p style="margin-left:2.8pt; margin-right:24.35pt">Nandigama (Village &amp; Mandal), Rangareddy District, Pin Code. 509228, Telangana, India.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2023.  
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">سافنتي هو دواء يحتوي على مثبط النبريلايسين ومستقبلات الأنجيوتنسين حيث انه يتكون من مادتين فعالتين هما ساكوبيتريل وفالسارتان.</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">يستخدم سافنتي لعلاج نوع من أنواع قصور القلب طويل الأمد لدى البالغين.</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">يحدث هذا النوع من القصور القلبي عندما يضعف القلب ولا يستطيع ضخ كمية كافية من الدم إلى الرئتين وباقي الجسم. يعد أكثر أعراض قصور القلب شيوعًا هو ضيق التنفس والتعب والإرهاق وتورم الكاحل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول سافنتي</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت تعاني من حساسية تجاه ساكوبيتريل أو فالسارتان أو أي من المكونات الأخرى لهذا الدواء (الواردة</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">في القسم 6).</p><p dir="RTL" style="margin-left:0cm; margin-right:16.0pt; text-align:right; text-indent:-9.0pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت تتناول نوعًا آخر من الأدوية المسماة بمثبطات الأنزيم المحول للأنجيوتنسين (مثل إنالابريل أو ليسينوبريل أو راميبريل). تُستخدم مثبطات الأنزيم المحول للأنجيوتنسين لعلاج ارتفاع ضغط الدم أو قصور القلب. إن كنت تتناول أحد مثبطات الأنزيم المحول للأنجيوتنسين، فانتظر لمدة 36 ساعة بعد تناول آخر جرعة قبل أن تبدأ في تناول سافنتي (انظر &quot;أدوية أخرى وسافنتي&quot;).</p><p dir="RTL" style="margin-left:24.5pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن أُصبت أو أصيب أحد أفراد عائلتك برد فعل يسمى الوذمة الوعائية (تورم الوجه و الشفتين و اللسان و/ أو الحلق، وصعوبات في التنفس) عند تناول مثبطات الأنزيم المحول للأنجيوتنسين أو موانع مستقبلات الأنجيوتنسين (ARB) (مثل فالسارتان أو تلميسارتان أو إربيسارتان).</p><p dir="RTL" style="margin-left:15.35pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت مصابًا بداء السكري أو بتدهور وظائف الكلى وتتم معالجتك باستخدام أحد أدوية خفض ضغط الدم التي تحتوي على أليسكيرين (انظر &quot;الأدوية الأخرى وسافنتي&quot;).</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت مصابًا بمرض كبدي بالغ.</p><p dir="RTL" style="margin-left:63.7pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن أتممتِ 3 أشهر من حملكِ (يفضل أيضًا تجنب هذا الدواء منذ بداية فترة الحمل، انظري &quot;الحمل والرضاعة&quot;).</p><p><strong>إن انطبقت عليك أي من الحالات المذكورة أعلاه، فلا تتناول سافنتي وتناقش مع طبيبك.</strong></p><p>&nbsp;</p><p><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">تناقش مع طبيبك أو الصيدلاني أو الممرض قبل أو أثناء تناول سافنتي:</p><p dir="RTL" style="margin-left:10.0pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كان يتم علاجك باستخدام موانع مستقبلات الأنجيوتنسين (ARB) أو أليسكيرين (انظر &quot;لا تتناول سافنتي&quot;).</p><p dir="RTL" style="margin-left:45.0pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن أصبت في أي وقت مضى بوذمة وعائية (انظر &quot;لا تتناول سافنتي&quot; والقسم 4 &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL" style="margin-left:31.6pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت مصابًا بانخفاض ضغط الدم أو تتناول أية أدوية أخرى تقلل ضغط الدم (مثل مدرات البول) أو كنت تعاني من القيء أو الإسهال -خاصة إن كنت تبلغ من العمر 65 عامًا أو أكثر- أو إن كنت مصابًا بمرض كلوي و ضغط دم منخفض.</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت مصابًا بمرض كلوي بالغ.</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت تعاني من الجفاف.</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت مصابًا بضيق الشريان الكلوي.</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت مصابًا بمرض كبدي.</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إن كنت مصابًا بالهلوسة أو الإرتياب أو تغيرات في نمط النوم.</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">قد يتابع طبيبك مستوى البوتاسيوم في دمك على فترات منتظمة أثناء تلقيك العلاج بسافنتي.</p><p><strong>إن انطبق عليك أي مما سبق، فأخبر طبيبك أو الصيدلاني أو الممرض قبل تناولك سافنتي.</strong></p><p>&nbsp;</p><p dir="RTL" style="margin-right:5.75pt; text-align:right"><strong>الأطفال والمراهقون</strong></p><p dir="RTL" style="margin-left:7.3pt; margin-right:5.75pt; text-align:right">لا تعطِ هذا الدواء للأطفال (الذين تقل أعمارهم عن 18 عامًا) لأنه لم يجر اختباره في هذه الفئة العمرية.</p><p>الأدوية الأخرى وسافنتي</p><p dir="RTL" style="margin-left:11.45pt; margin-right:5.75pt; text-align:justify">أخبر طبيبك أو الصيدلاني أو الممرض إن كنت تتناول أو تناولت مؤخرًا أو قد تتناول أية أدوية أخرى. قد يلزم تغيير الجرعة أو اتخاذ احتياطات أخرى أو حتى التوقف عن تناول أحد الأدوية. يجب فعل هذا خصوصًا مع الأدوية التالية:</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:justify"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->مثبطات الأنزيم المحول للأنجيوتنسين. لا تتناول سافنتي مع مثبطات الأنزيم المحول للأنجيوتنسين. إن كنت تتناول مثبطات الأنزيم المحول للأنجيوتنسين، فانتظر 36 ساعة بعد تناول آخر جرعة من مثبط الأنزيم المحول للأنجيوتنسين قبل البدء في تناول سافنتي (انظر &quot;لا تتناول سافنتي&quot;). إن توقفت عن تناول سافنتي، فانتظر 36 ساعة بعد تناول آخر جرعة من سافنتي قبل البدء في تناول مثبطات الأنزيم المحول للأنجيوتنسين.</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->الأدوية الأخرى المستخدمة لعلاج قصور القلب أو خفض ضغط الدم، مثل موانع مستقبلات الأنجيوتنسين أو أليسكيرين (انظر &quot;لا تتناول سافنتي&quot;).</p><p dir="RTL" style="margin-left:37.95pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->بعض الأدوية المعروفة باسم الستاتينات التي تستخدم لخفض مستويات الكوليسترول المرتفعة (على سبيل المثال أتورفاستاتين).</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->سيلدينافيل، وهو دواء يستخدم لعلاج ضعف الانتصاب أو ارتفاع ضغط الدم الرئوي.</p><p dir="RTL" style="margin-left:37.65pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->الأدوية التي تزيد مستوى البوتاسيوم في الدم، وتشمل مكملات البوتاسيوم وبدائل الملح التي تحتوي على البوتاسيوم والأدوية التي تدخر البوتاسيوم والهيبارين.</p><p dir="RTL" style="margin-left:11.15pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->مسكنات الألم من النوع المسمى مضادات الالتهاب غير الستيرويدية (NSAIDs) أو مثبطات أنزيمات الأكسدة الحلقية 2 الانتقائية. إن كنت تتناول أحد هذه الأدوية، فقد يرغب طبيبك في فحص وظائف الكلى عند بدء العلاج أو إجراء تعديلات على علاجك (انظر &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->الليثيوم، وهو دواء يستخدم لعلاج بعض أنواع الأمراض النفسية.</p><p dir="RTL" style="margin-left:18.85pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->فيوروسيميد، وهو دواء ينتمي إلى مجموعة مدرات البول التي تستخدم لزيادة كمية البول الخارج من الجسم.</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->النيتروجليسرين، وهو دواء يستخدم لعلاج الذبحة الصدرية.</p><p dir="RTL" style="margin-left:11.8pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->بعض أنواع المضادات الحيوية (مجموعة ريفاميسين) أو سيكلوسبورين (يستخدم لمنع حدوث رفض للأعضاء المزروعة) أو مضادات الفيروسات مثل ريتونافير (يستخدم لعلاج فيروس نقص المناعة البشرية / الإيدز).</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->ميتفورمين، وهو دواء يستخدم لعلاج داء السكري.</p><p><strong>إن انطبق عليك أي مما سبق، فأخبر طبيبك أو الصيدلاني قبل تناول سافنتي.</strong></p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right"><u>الحمل</u></p><p dir="RTL" style="margin-left:7.3pt; margin-right:5.75pt; text-align:right">يجب عليكِ إخبار طبيبكِ إن كنتِ تعتقدين أنكِ (أو قد تصبحين) حاملًا. سوف ينصحك طبيبك عادةً بالتوقف عن تناول هذا الدواء قبل فترة الحمل أو بمجرد علمكِ بذلك كما سوف ينصحكِ بتناول دواء آخر بدلاً من سافنتي.</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">لا يُنصح بهذا الدواء في بداية فترة الحمل، ويجب عدم تناوله بعد مرور 3 أشهر من حدوث الحمل؛ حيث أنه قد يسبب ضررًا بالغًا لطفلك إن استخدم بعد شهر الحمل الثالث.</p><p>&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right"><u>الرضاعة الطبيعية</u></p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">لا ينصح باستخدام سافنتي للأمهات المرضعات. أخبري طبيبكِ إن كنت تمارسين أو على وشك البدء في الرضاعة الطبيعية.</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">قبل أن تقود السيارة أو تستخدم الأدوات أو تشغل الآلات أو تؤدي أنشطة أخرى تتطلب التركيز، فتأكد من علمك بكيفية تأثير سافنتي عليك. إن شعرت بدوار أو إرهاق شديد أثناء تناول هذا الدواء، فامتنع عن قيادة أى مركبة أو ركوب الدراجة أو استخدام أية أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:34.05pt; margin-right:5.75pt; text-align:right">احرص دائمًا على تناول هذا الدواء تمامًا مثلما أخبرك طبيبك أو الصيدلاني. واستشر طبيبك أو الصيدلاني إن لم تكن متأكدًا.</p><p dir="RTL" style="margin-left:7.3pt; margin-right:5.75pt; text-align:right">ستبدأ عادة بتناول 24 ملغم / 26 ملغم أو 49 ملغم / 51 ملغم مرتين في اليوم (قرص واحد في الصباح و قرص واحد في المساء). سيقرر طبيبك جرعة البدء الدقيقة بناءً على الأدوية التي كنت تتناولها سابقًا. سيقوم طبيبك بعد ذلك بتعديل الجرعة اعتمادًا على استجابتك للعلاج حتى الوصول إلى الجرعة المناسبة لك.</p><p dir="RTL" style="margin-left:10.4pt; margin-right:5.75pt; text-align:right">الجرعة المعتادة الموصى بها هي 97 ملغم / 103 ملغم مرتين في اليوم (قرص واحد في الصباح وقرص واحد في المساء).</p><p dir="RTL" style="margin-left:7.3pt; margin-right:5.75pt; text-align:right">يمكن أن يصاب المرضى الذين يتناولون سافنتي بانخفاض ضغط الدم (الإحساس بدوخة ودوار) أو ارتفاع مستوى البوتاسيوم في الدم (يمكن اكتشافه عندما يجري طبيبك فحص الدم) أو تراجع وظائف الكلى. إن حدث هذا، فقد يقلل طبيبك جرعة أي دواء آخر تتناوله أو يقلل مؤقتًا جرعة سافنتي أو يوقفه تمامًا.</p><p dir="RTL" style="margin-left:7.3pt; margin-right:5.75pt; text-align:right">ابتلع الأقراص مع كوب من الماء. يمكنك تناول سافنتي مع الطعام أو بدونه.لا يُنصح بتكسير الأقراص أو سحقها.</p><p><strong>إن تناولت سافنتي بجرعة أكبر مما ينبغي</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">إن تناولت عن طريق الخطأ الكثير من سافنتي، أو إن تناول شخص آخر أقراصك، فاتصل بطبيبك على الفور. إن أصبت بدوخة شديدة و/ أو إغماء، فأخبر طبيبك بأسرع ما يمكن وابقَ مستلقيًا.</p><p><strong>إن نسيت تناول سافنتي</strong></p><p dir="RTL" style="margin-left:7.3pt; margin-right:5.75pt; text-align:right">يُنصح بتناول دوائك في نفس الوقت من كل يوم. مع ذلك، إن نسيت تناول جرعة، فعليك ببساطة تناول الجرعة التالية في الوقت المحدد. لا تأخذ جرعة مضاعفة لتعويض جرعة منسية.</p><p><strong>إن توقفت عن تناول سافنتي</strong></p><p dir="RTL" style="margin-left:31.5pt; margin-right:5.75pt; text-align:right">قد يؤدي إيقاف العلاج بسافنتي إلى تدهور حالتك. لا تتوقف عن تناول دوائك ما لم يخبرك طبيبك بذلك.</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">إن كانت لديك أية استفسارات أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلاني</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-right:16.0pt; text-align:right; text-indent:-7.0pt">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب بأعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p style="text-align:right">&nbsp;</p><p>قد تكون بعض الآثار الجانبية خطيرة</p><p dir="RTL" style="margin-left:24.8pt; margin-right:5.75pt; text-align:right; text-indent:0cm">توقف عن تناول سافنتي واطلب الرعاية الطبية على الفور إن لاحظت أي تورم في الوجه و/ أو الشفتين و/ أو اللسان و/ أو الحلق والذي قد يسبب صعوبات في التنفس أو البلع. قد تكون هذه علامات حدوث وذمة وعائية (عرض جانبي غير شائع قد يصيب ما يصل إلى 1 من كل 100 شخص).</p><p dir="RTL" style="margin-left:24.8pt; margin-right:5.75pt; text-align:right; text-indent:0cm">الآثار الجانبية المحتملة الأخرى:</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">إن تفاقمت أي من الآثار الجانبية المذكورة أدناه، فأخبر طبيبك أو الصيدلاني.</p><p>&nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right"><strong><u>آثار جانبية شائعة جدًا</u></strong><u> </u><u>(قد تصيب أكثر من</u><u> </u><u>شخص</u><u> </u><u>من كل</u><u> 10 </u><u>أشخاص)</u></p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->انخفاض ضغط الدم (دوخة، شعور بالإغماء)</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->ارتفاع مستوى البوتاسيوم في الدم (يظهر في فحص الدم)</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->تراجع وظائف الكلى (القصور الكلوي)</p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right"><strong><u>آثار جانبية شائعة</u></strong><strong><u> </u></strong><u>(قد تظهر لدى ما يصل إلى</u><u> 1 </u><u>من كل</u><u> 10 </u><u>أشخاص)</u></p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->سعال</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->دوخة</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إسهال</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->انخفاض مستوى خلايا الدم الحمراء (يظهر في فحص الدم)</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->تعب</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->فشل كلوي (حاد) (اضطراب كلوي خطير)</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->انخفاض مستوى البوتاسيوم في الدم (يظهر في فحص الدم)</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->صداع</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->إغماء</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->ضعف</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->شعور بالغثيان</p><p dir="RTL" style="margin-left:55.3pt; margin-right:5.75pt; text-align:right; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->انخفاض ضغط الدم (دوخة، شعور بالإغماء) عند تغيير وضع الجسم من وضعية الجلوس أو الاستلقاء إلى وضعية الوقوف</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->التهاب المعدة (ألم المعدة، غثيان)</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->الإحساس بالدوران</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->انخفاض مستوى السكر في الدم (يظهر في فحص الدم)</p><p style="text-indent:0cm"><strong><u>آثار جانبية غير شائعة</u></strong><strong><u> </u></strong><u>(قد تظهر لدى ما يصل إلى</u><u> 1 </u><u>من كل</u><u> 100 </u><u>شخص)</u></p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->رد فعل تحسسي مع طفح جلدي وحكة</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->دوار عند تغيير وضع الجسم من وضعية الجلوس إلى وضعية الوقوف</p><p style="text-indent:0cm"><strong><u>آثار جانبية نادرة</u></strong><u> </u><u>(قد تظهر لدى ما يصل إلى</u><u> 1 </u><u>من كل</u><u> 1000 </u><u>شخص)</u></p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->هلوسة</p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->تغيرات في نمط النوم</p><p style="text-indent:0cm"><strong><u>آثار جانبية نادرة جدًا</u><u> </u></strong><u>(قد تظهر لدى ما يصل إلى</u><u> 1 </u><u>من كل</u><u> 10000 </u><u>شخص)</u></p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->جنون الارتياب (البارانويا)</p><p style="margin-left:0cm">&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL" style="margin-left:0cm; text-align:justify">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ &lt;طبيبك، أو مقدم الرعاية الصحية&gt; &lt;أو&gt; &lt;الصيدلي&gt;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right">احفظ هذا الدواء بعيدًا عن متناول الأطفال.</p><p dir="RTL" style="margin-left:7.3pt; margin-right:0cm; text-align:right">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وشريط الدواء بعد الرمز EXP. يشير الى انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL" style="margin-left:7.3pt; margin-right:0cm; text-align:right">لا تخزنه في درجة حرارة أكبر من 30&deg; درجة مئوية</p><p dir="RTL" style="margin-left:106.1pt; text-align:right">لا يتطلب هذا الدواء أي شروط خاصة لدرجة حرارة التخزين. خزنه في العبوة الأصلية لحمايته من الرطوبة.</p><p dir="RTL" style="margin-left:34.05pt; margin-right:0cm; text-align:right">لا تستخدم هذا الدواء إن لاحظت تلفًا في العبوة أو وجود علامات تلاعب. لا ترمِ الأدوية في مياه الصرف الصحي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>علام تحتوي أقراص سافنتي المغلفة</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:13.8pt; text-align:right"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->المادة الفعالة هي ساكوبيتريل وفالسارتان.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p dir="RTL" style="margin-left:258.95pt; margin-right:5.75pt; text-align:right"><u>سافنتي أقراص 24 ملغم / 26 ملغم</u></p><p dir="RTL" style="margin-left:117.0pt; margin-right:5.75pt; text-align:right">&nbsp;يحتوي كل قرص مغلف على ساكوبيتريل 24 ملغم وفالسارتان 26 ملغم</p><p dir="RTL" style="margin-left:258.95pt; margin-right:5.75pt; text-align:right"><u>سافنتي أقراص 49 ملغم / 51 ملغم</u></p><p dir="RTL" style="margin-left:112.5pt; margin-right:5.75pt; text-align:right">يحتوي كل قرص مغلف على ساكوبيتريل 49 ملغم وفالسارتان 51 ملغم</p><p style="margin-left:0cm; margin-right:257.1pt"><u>&nbsp;</u></p><p dir="RTL" style="margin-left:257.1pt; margin-right:5.75pt; text-align:right"><u>سافنتي أقراص 97 ملغم / 103 ملغم</u></p><p dir="RTL" style="margin-left:135.0pt; margin-right:5.75pt; text-align:right">يحتوي كل قرص مغلف على ساكوبيتريل 97 ملغم وفالسارتان 103 ملغم</p><p>&nbsp;</p><p dir="RTL" style="text-align:right"><u>مكونات أخرى:<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></u></p><p dir="RTL" style="margin-left:0cm; margin-right:5.75pt; text-align:right"><u>لُب القرص</u></p><p dir="RTL" style="margin-left:7.3pt; margin-right:5.75pt; text-align:right">سليلوز دقيق التبلور (PH 112)، كروسبوفيدون، كروسكارميلوز الصوديوم، ثاني أكسيد السيليكون الغرواني، التلك، ستيرات المغنيسيوم، ماء نقي.</p><p dir="RTL" style="margin-right:5.75pt; text-align:right"><u>الغلاف:</u></p><p dir="RTL" style="margin-left:146.05pt; margin-right:5.75pt; text-align:right">سافنتي أقراص 24 ملغم / 26 ملغم: Opadry Purple 03F500057</p><p dir="RTL" style="margin-left:146.05pt; margin-right:5.75pt; text-align:right">سافنتي أقراص 49 ملغم / 51 ملغم: Opadry Yellow 03F520058</p><p>سافنتي أقراص 97 ملغم / 103 ملغم: Opadry Pink 03F540048</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:399.35pt; margin-right:5.75pt; text-align:right">أقراص مغلفة</p><p dir="RTL" style="margin-left:311.1pt; margin-right:5.75pt; text-align:right"><u>العبوة:</u></p><p dir="RTL" style="margin-left:311.1pt; margin-right:5.75pt; text-align:right">عبوة الحاوية من البولي إيثيلين عالي الكثافة 60&#39;s 180&#39;s. عبوة الشريط 10&#39;s</p><p>ملاحظة: قد لا تتوفر جميع أحجام العبوات في المتجر</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:#ededed; border-color:black; height:19.1pt; width:240.9pt"><p dir="RTL" style="margin-left:0cm; margin-right:2.8pt; text-align:right">حامل ترخيص التسويق</p></td><td style="background-color:#ededed; border-color:black; height:19.1pt; width:241.0pt"><p dir="RTL" style="margin-left:0cm; margin-right:2.8pt; text-align:right">المصنّع</p></td></tr><tr><td style="border-color:black; height:122.55pt; vertical-align:top; width:240.9pt"><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:center"><strong>شركة سدير فارما (</strong><strong>SPC</strong><strong>)</strong> </p><p dir="RTL" style="margin-left:0cm; margin-right:6.0pt; text-align:center">طريق الملك فهد، حي الملك فهد، مبنى رقم: 7639، صندوق بريد: 12262، الرياض، المملكة العربية السعودية</p><p dir="RTL" style="margin-left:0cm; margin-right:6.0pt; text-align:center">هاتف: 920001432-11-966 + </p><p dir="RTL" style="margin-left:0cm; margin-right:6.0pt; text-align:center">فاكس: 4668195-11-966 + </p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:center">البريد الإلكتروني: info@sudairpharma.com</p></td><td style="height:122.55pt; vertical-align:top; width:241.0pt"><p dir="RTL" style="margin-left:0cm; margin-right:2.8pt; text-align:center"><strong>مختبرات إم إس إن الخاصة المحدودة</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:2.8pt; text-align:center">قسم التركیبات، الوحدة الثانیة، سي. رقم 1277 و 1319 إلى</p><p dir="RTL" style="margin-left:0cm; margin-right:2.8pt; text-align:center">1324 ، ناندیغاما (فیلدج آند ماندال)،</p><p dir="RTL" style="margin-left:0cm; margin-right:2.8pt; text-align:center">، منطقة رانجاریدي، رقم الفھرس البریدي 509228</p><p dir="RTL" style="margin-left:24.35pt; margin-right:2.8pt; text-align:center">تیلانجانا، الھند.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجعت هذه النشرة لآخر مرة في يناير 2023.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saventi 24 mg/26 mg film-coated tablets
Saventi 49 mg/51 mg film-coated tablets
Saventi 97 mg/103 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saventi 24 mg/ 26 mg film-coated tablets 
Each film Coated tablet Contains Sacubitril 24 mg and Valsartan 26 mg

Saventi 49 mg/51 mg film-coated tablets
Each film Coated tablet Contains Sacubitril 49 mg and Valsartan 51 mg

Saventi 97 mg/103 mg film-coated tablets
Each film Coated tablet Contains Sacubitril 97 mg and Valsartan 103 mg

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet

Saventi 24 mg/26 mg film-coated tablets 
Purple colored, Oval shaped, biconvex, film coated tablets one side debossed with "M" and other side debossed with "S1" and free from physical defects.

Saventi 49 mg/51 mg film-coated tablets
Light yellow to yellow colored, Oval shaped, biconvex, film coated tablets one side debossed with "M" and other side debossed with "S2" and free from physical defects.

Saventi 97 mg/103 mg film-coated tablets
Light pink to pink colored, Oval shaped, biconvex, film coated tablets one side debossed with "M" and other side debossed with "S3" free from physical defects.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Saventi is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>The recommended starting dose of Saventi is one tablet of 49 mg/51 mg twice daily, except in the situations described below. The dose should be doubled at 2-4 weeks to the target dose of one tablet of 97 mg/103 mg twice daily, as tolerated by the patient (see section 5.1).</p><p>If patients experience tolerability issues (systolic blood pressure [SBP] &le;95 mmHg, symptomatic hypotension, hyperkalaemia, renal dysfunction), adjustment of concomitant medicinal products, temporary down&ndash;titration or discontinuation of Saventi is recommended (see section 4.4).</p><p>In PARADIGM-HF study, Saventi was administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin II receptor Blocker (ARB)(see section 5.1). There is limited experience in patients not currently taking an ACE inhibitor or an ARB or taking low doses of these medicinal products, therefore a starting dose of 24 mg/26 mg twice daily and slow dose titration (doubling every 3-4 weeks) are recommended in these patients (see &ldquo;Titration&rdquo; in section 5.1).</p><p>Treatment should not be initiated in patients with serum potassium level &gt;5.4 mmol/l or with SBP</p><p>&lt;100 mmHg (see section 4.4). A starting dose of 24 mg/26 mg twice daily should be considered for patients with SBP &ge;100 to 110 mmHg.</p><p>Saventi should not be co-administered with an ACE inhibitor or an ARB. Due to the potential risk of angioedema when used concomitantly with an ACE inhibitor, it must not be started for at least 36 hours after discontinuing ACE inhibitor therapy (see section 4.3, 4.4 and 4.5)</p><p>The valsartan contained within Saventi is more bioavailable than the valsartan in other marketed tablet formulations (see section 5.2).</p><p>If a dose is missed, the patient should take the next dose at the scheduled time.</p><p>Splitting or crushing of the tablets is not recommended.</p><p><u>Special populations</u> Elderly population</p><p>The dose should be in line with the renal function of the elderly patient.</p><p>&nbsp;</p><p><strong>Renal impairment</strong></p><p>No dose adjustment is required in patients with mild (Estimated Glomerular Filtration Rate [eGFR] 60-90 ml/min/1.73 m<sup>2</sup>) renal impairment. A starting dose of 24 mg/26 mg twice daily should be considered in patients with moderate renal impairment (eGFR 30-60 ml/min/1.73 m<sup>2</sup>). As there is very limited clinical experience in patients with severe renal impairment (eGFR &lt;30 ml/min/1.73 m<sup>2</sup>) (see section 5.1) Saventi should be used with caution and a starting dose of 24 mg/26 mg twice daily is recommended.</p><p>There is no experience in patients with end-stage renal disease and use of Saventi is not recommended.</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>No dose adjustment is required when administering Saventi to patients with mild hepatic impairment (Child-Pugh A classification). There is limited clinical experience in patients with moderate hepatic impairment (Child-Pugh B classification) or with AST/ALT values more than twice the upper limit of the normal range. Saventi should be used with caution in these patients and the recommended starting dose is 24 mg/26 mg twice daily (see sections 4.4 and 5.2).</p><p>Saventi is contraindicated in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (Child-Pugh C classification) (see section 4.3).</p><p><strong><u>Paediatric population</u></strong></p><p>The safety and efficacy of Saventi in children and adolescents aged below 18 years have not been established. No data are available.</p><p><strong><u>Method of administration</u></strong></p><p>Oral use.</p><p>Saventi may be administered with or without food (see section 5.2). The tablets must be swallowed with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
•	Concomitant use with ACE inhibitors (see sections 4.4 and 4.5). Saventi must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
•	Known history of angioedema related to previous ACE inhibitor or ARB therapy (see section 4.4).
•	Hereditary or idiopathic angioedema (see section 4.4).
•	Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see sections 4.4 and 4.5).
•	Severe hepatic impairment, biliary cirrhosis and cholestasis (see section 4.2).
•	Second and third trimester of pregnancy (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>&bull;&nbsp;&nbsp;&nbsp;The combination of Sacubitril/Valsartan with an ACE inhibitor is contraindicated due to the increased risk of angioedema (see section 4.3). Sacubitril/Valsartan must not be initiated until 36 hours after taking the last dose of ACE inhibitor therapy. If treatment with Sacubitril/Valsartan is stopped, ACE inhibitor therapy must not be initiated until 36 hours after the last dose of Sacubitril/Valsartan (see sections 4.2, 4.3 and 4.5).</p><p>&bull;&nbsp;&nbsp;&nbsp;The combination of Sacubitril/Valsartan with direct renin inhibitors such as aliskiren is not recommended (see section 4.5). The combination of Sacubitril/Valsartan with aliskiren-containing medicinal products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR &lt;60 ml/min/1.73 m<sup>2</sup>) (see sections 4.3 and 4.5).</p><p>&bull;&nbsp;&nbsp;&nbsp;Saventi contains valsartan, and therefore should not be co-administered with another ARB containing medicinal product (see section 4.2 and 4.5)</p><p><u>Hypotension</u></p><p>Treatment should not be initiated unless SBP is &ge;100 mmHg. Patients with SBP &lt;100 mmHg were not studied (see section 5.1). Cases of symptomatic hypotension have been reported in patients treated with Saventi during clinical studies (see section 4.8), especially in patients &ge;65 years old, patients with renal disease and patients with low SBP (&lt;112 mmHg). When initiating therapy or during dose titration with Sacubitril/Valsartan, blood pressure should be monitored routinely. If hypotension occurs, temporary down-titration or discontinuation of sacubitril/valsartan is recommended (see section 4.2). Dose adjustment of diuretics, concomitant antihypertensives and treatment of other causes of hypotension (e.g. hypovolaemia) should be considered. Symptomatic hypotension is more likely to occur if the patient has been volume-depleted, e.g. by diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Sodium and/or volume depletion should be corrected before starting treatment with Sacubitril/Valsartan, however, such corrective action must be carefully weighed against the risk of volume overload.</p><p><u>Impaired renal function</u></p><p>Evaluation of patients with heart failure should always include assessment of renal function. Patients with mild and moderate renal impairment are more at risk of developing hypotension (see section 4.2). There is very limited clinical experience in patients with severe renal impairment (estimated GFR &lt;30 ml/min/1.73m<sup>2</sup>) and these patients may be at greatest risk of hypotension (see section 4.2). There is no experience in patients with end-stage renal disease and use of Sacubitril/Valsartan is not recommended.</p><p><u>Worsening renal function</u></p><p>Use of Sacubitril/Valsartan may be associated with decreased renal function. The risk may be further increased by dehydration or concomitant use of non-steroidal anti-inflammatory agents (NSAIDs) (see section 4.5). Down-titration should be considered in patients who develop a clinically significant decrease in renal function.</p><p><u>Hyperkalaemia</u></p><p>Treatment should not be initiated if the serum potassium level is &gt;5.4 mmol/l. Use of Sacubitril/Valsartan may be associated with an increased risk of hyperkalaemia, although hypokalaemia may also occur (see section 4.8). Monitoring of serum potassium is recommended, especially in patients who have risk factors such as renal impairment, diabetes mellitus or hypoaldosteronism or who are on a high potassium diet or on mineralocorticoid antagonists (see section 4.2). If patients experience clinically significant hyperkalaemia adjustment of concomitant medicinal products, or temporary down&ndash;titration or discontinuation is recommended. If serum potassium level is &gt;5.4 mmol/l discontinuation should be considered.</p><p><u>Angioedema</u></p><p>Angioedema has been reported in patients treated with Sacubitril/Valsartan. If angioedema occurs, Sacubitril/Valsartan should be immediately discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. It must not be re-administered. In cases of confirmed angioedema where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal oedema may be fatal. Where there is involvement of the tongue, glottis or larynx likely to cause airway obstruction, appropriate therapy, e.g. adrenaline solution 1 mg/1 ml (0.3-0.5 ml), and/or measures necessary to ensure a patent airway, should be promptly administered.</p><p>Patients with a prior history of angioedema were not studied. As they may be at higher risk for angioedema, caution is recommended if Sacubitril/Valsartan is used in these patients. Sacubitril/Valsartan is contraindicated in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy or with hereditary or idiopathic angioedema (see section 4.3).</p><p>Black patients have an increased susceptibility to develop angioedema (see section 4.8).</p><p><u>Patients with renal artery stenosis</u></p><p>Sacubitril/valsartan may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis. Caution is required in patients with renal artery stenosis and monitoring of renal function is recommended.</p><p><u>Patients with NYHA functional classification IV</u></p><p>Caution should be exercised when initiating Sacubitril/valsartan in patients with NYHA functional classification IV due to limited clinical experience in this population.</p><p><u>B-type natriuretic peptide (BNP)</u></p><p>BNP is not a suitable biomarker of heart failure in patients treated with Sacubitril/valsartan because it is a neprilysin substrate (see section 5.1).</p><p><u>Patients with hepatic impairment</u></p><p>There is limited clinical experience in patients with moderate hepatic impairment (Child-Pugh B classification) or with AST/ALT values more than twice the upper limit of the normal range. In these patients, exposure may be increased and safety is not established. Caution is therefore recommended when using it in these patients (see section 4.2 and 5.2). Sacubitril/valsartan is contraindicated in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (Child-Pugh C classification) (see section 4.3).</p><p><u>Psychiatric disorders</u></p><p>Psychiatric events such as hallucinations, paranoia and sleep disorders, in context of psychotic events, have been associated with sacubitril/valsartan use. If a patient experiences such events, discontinuation of sacubitril/valsartan treatment should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions resulting in a contraindication</u></p><p><em>ACE inhibitors</em></p><p>The concomitant use of sacubitril/valsartan with ACE inhibitors is contraindicated, as the concomitant inhibition of neprilysin (NEP) and ACE may increase the risk of angioedema.</p><p>sacubitril/valsartan must not be started until 36 hours after taking the last dose of ACE inhibitor therapy. ACE inhibitor therapy must not be started until 36 hours after the last dose of sacubitril/valsartan Tablets (see sections 4.2 and 4.3).</p><p><em>Aliskiren</em></p><p>The concomitant use of sacubitril/valsartan with aliskiren-containing medicinal&nbsp;products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR &lt;60 ml/min/1.73 m<sup>2</sup>) (see section 4.3). The combination of sacubitril/valsartan with direct renin inhibitors such as aliskiren is not recommended (see section 4.4). Combination of sacubitril/valsartan with aliskiren is potentially associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Interactions resulting in concomitant use not being recommended</u></p><p>sacubitril/valsartan contains valsartan, and therefore should not be co-administered with another ARB containing product (see section 4.4).</p><p><u>Interactions requiring precautions</u></p><p><em>OATP1B1 and OATP1B3 substrates, e.g. statins</em></p><p><em>In vitro </em>data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. sacubitril/valsartan Tablets may therefore increase the systemic exposure of OATP1B1 and OATP1B3</p><p>substrates such as statins. Co-administration of sacubitril/valsartan increased the C<sub>max</sub> of atorvastatin and its metabolites by up to 2-fold and AUC by up to 1.3-fold. Caution should be exercised when co- administering sacubitril/valsartan with statins. No clinically relevant interaction was observed when simvastatin and sacubitril/valsartan Tablets were co-administered.</p><p><em>PDE5 inhibitors including sildenafil</em></p><p>Addition of a single dose of sildenafil to sacubitril/valsartan at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of sacubitril/valsartan alone. Therefore, caution should be exercised when sildenafil or another PDE5 inhibitor is initiated in patients treated with sacubitril/valsartan.</p><p><em>Potassium</em></p><p>Concomitant use of potassium-sparing diuretics (triamterene, amiloride), mineralocorticoid antagonists (e.g. spironolactone, eplerenone), potassium supplements, salt substitutes containing potassium or other agents (such as heparin) may lead to increases in serum potassium, and to increases in serum creatinine. Monitoring of serum potassium is recommended if sacubitril/valsartan is co-administered with these agents (see section 4.4).</p><p><em>Non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 (COX-2) inhibitors</em></p><p>In elderly patients, volume-depleted patients (including those on diuretic therapy), or patients with compromised renal function, concomitant use of sacubitril/valsartan and NSAIDs may lead to an increased risk of worsening of renal function.</p><p>Therefore, monitoring of renal function is recommended when initiating or modifying treatment in patients on sacubitril/valsartan who are taking NSAIDs concomitantly (see section 4.4).</p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors or angiotensin II receptor antagonists including sacubitril/valsartan.</p><p>Therefore, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased further.</p><p>&nbsp;</p><p><em>Furosemide</em></p><p>Co-administration of sacubitril/valsartan and furosemide had no effect on the pharmacokinetics of sacubitril/valsartan but reduced C<sub>max</sub> and AUC of furosemide by 50% and 28%, respectively. While there was no relevant change in urine volume, the urinary excretion of sodium was reduced within 4 hours and 24 hours after co-administration. The average daily dose of furosemide was unchanged from baseline until the end of the PARADIGM-HF study in patients treated with sacubitril/valsartan.</p><p><em>Nitrates, e.g. nitroglycerine</em></p><p>There was no drug-drug interaction between sacubitril/valsartan and intravenously administered nitroglycerin with regard to blood pressure reduction. Co-administration of nitroglycerin and sacubitril/valsartan was associated with a treatment difference of 5 bpm in heart rate compared to the administration of nitroglycerine alone. A similar effect on the heart rate may occur when sacubitril/valsartan is co-administered with sublingual, oral or transdermal nitrates. In general, no dose adjustment is required.</p><p><em>OATP and MRP2 transporters</em></p><p>The active metabolite of sacubitril (LBQ657) and valsartan are OATP1B1, OATP1B3, OAT1 and OAT3 substrates; valsartan is also a MRP2 substrate. Therefore, co-administration of sacubitril/valsartan with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir, cidofovir) or MRP2 (e.g. ritonavir) may increase the systemic exposure of LBQ657 or valsartan. Appropriate care should be exercised when initiating or ending concomitant treatment with such medicinal products.</p><p><em>Metformin</em></p><p>Co-administration of sacubitril/valsartan with metformin reduced both C<sub>max</sub> and AUC of metformin by 23%. The clinical relevance of these findings is unknown. Therefore, when initiating therapy with sacubitril/valsartan in patients receiving metformin, the clinical status of the patient should be evaluated.</p><p><u>No significant interaction</u></p><p>No clinically meaningful drug-drug interaction was observed when sacubitril/valsartan was co-administered with digoxin, warfarin, hydrochlorothiazide, amlodipine, omeprazole, carvedilol or a combination of levonorgestrel/ethinyl estradiol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>&nbsp;Pregnancy</u></p><p>The use of sacubitril/valsartan is not recommended during the first trimester of pregnancy and is contraindicated during the second and third trimesters of pregnancy (see section 4.3).</p><p><em>Valsartan</em></p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with ARBs, similar risks may exist for this class of medicinal product. Unless continued ARB therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ARBs should be stopped immediately and, if appropriate, alternative therapy should be started. Exposure to ARBs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).</p><p>Should exposure to ARBs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken ARBs should be closely observed for hypotension (see section 4.3).</p><p><em>Sacubitril</em></p><p>There are no data from the use of sacubitril in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p><em>Sacubitril/Valsartan </em></p><p>There are no data from the use of sacubitril/valsartan in pregnant women. Animal studies with sacubitril/valsartan have shown reproductive toxicity (see section 5.3).</p><p><u>Breast-feeding</u></p><p>It is not known whether sacubitril/valsartan is excreted in human milk. The components of sacubitril/valsartan Tablets, sacubitril and valsartan, were excreted in the milk of lactating rats (see section 5.3). Because of the potential risk for adverse reactions in breast-fed newborns/infants, it is not recommended during breast-feeding. A decision should be made whether to abstain from breast-feeding or to discontinue sacubitril/valsartan while breast- feeding, taking into account the importance of sacubitril/valsartan to the mother.</p><p><u>Fertility</u></p><p>There are no available data on the effect of sacubitril/valsartan on human fertility. No impairment of fertility was demonstrated in studies with it in male and female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>sacubitril/valsartan has a minor influence on the ability to drive and use machines. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or fatigue may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions during treatment with sacubitril/valsartan were hypotension (17.6%), hyperkalaemia (11.6%) and renal impairment (10.1%) (see section 4.4). Angioedema was reported in patients treated with sacubitril/valsartan (0.5%) (see description of selected adverse reactions).</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are ranked by System organ class and then by frequency with the most frequent first, using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000). Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p><strong>Table 1 List of adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Preferred term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Hyperkalaemia*</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness postural</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Vascular</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Hypotension*</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema*</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>Renal impairment*</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Renal failure (renal failure,</p><p>acute renal failure)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site</strong></p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>conditions</strong></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><sup>*</sup>See description of selected adverse reactions.</p><p><sup>**</sup>Including auditory and visual hallucinations</p><p><u>Description of selected adverse reactions</u></p><p><em>Angioedema</em></p><p>Angioedema has been reported in patients treated with sacubitril/valsartan. In PARADIGM-HF, angioedema was reported in 0.5% of patients treated with sacubitril/valsartan, compared with 0.2% of patients treated with enalapril. A higher incidence of angioedema was observed in Black patients treated with sacubitril/valsartan (2.4%) and enalapril (0.5%) (see section 4.4).</p><p><em>Hyperkalaemia and serum potassium</em></p><p>In PARADIGM-HF, hyperkalaemia and serum potassium concentrations &gt;5.4 mmol/l were reported in 11.6% and 19.7% of sacubitril/valsartan-treated patients and 14.0% and 21.1% of enalapril-treated patients, respectively.</p><p><em>Blood pressure</em></p><p>In PARADIGM-HF, hypotension and clinically relevant low systolic blood pressure (&lt;90mmHg and decrease from baseline of &gt;20 mmHg) were reported in 17.6% and 4.76% of sacubitril/valsartan-treated patients compared with 11.9% and 2.67% of enalapril-treated patients, respectively.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In PARADIGM-HF, renal impairment was reported in 10.1% of sacubitril/valsartan-treated patients and 11.5% of enalapril-treated patients.</p><p>&nbsp;</p><p><u>To reports any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa/</u></p><p><strong>Other GCC States:&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available with regard to overdose in humans. A single dose of 583 mg sacubitril/617 mg valsartan and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) were studied in healthy volunteers and were well tolerated.</p><p>Hypotension is the most likely symptom of overdose due to the blood pressure lowering effects of sacubitril/valsartan. Symptomatic treatment should be provided.</p><p>The medicinal product is unlikely to be removed by haemodialysis due to high protein binding (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; angiotensin II receptor blockers , other combinations, ATC code: C09DX04</p><p><u>Mechanism of action</u></p><p>Sacubitril/valsartan exhibits the mechanism of action of an angiotensin receptor neprilysin inhibitor by simultaneously inhibiting neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and by blocking the angiotensin II type-1 (AT1) receptor via valsartan. The complementary cardiovascular benefits of sacubitril/valsartan in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by LBQ657 and the simultaneous inhibition of the effects of angiotensin II by valsartan. NPs exert their effects by activating membrane-bound guanylyl cyclase-coupled receptors, resulting in increased concentrations of the second messenger cyclic guanosine monophosphate (cGMP), which could result in vasodilation, natriuresis and diuresis, increased glomerular filtration rate and renal blood flow, inhibition of renin and aldosterone release, reduction of sympathetic activity, and anti-hypertrophic and anti-fibrotic effects.</p><p>&nbsp;</p><p>Valsartan inhibits detrimental cardiovascular and renal effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.</p><p>This prevents sustained activation of the renin- angiotensin-aldosterone system that would result in vasoconstriction, renal sodium and fluid retention, activation of cellular growth and proliferation, and subsequent maladaptive cardiovascular remodelling.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The pharmacodynamic effects of sacubitril/valsartan were evaluated after single and multiple dose administrations in healthy subjects and in patients with heart failure, and are consistent with simultaneous neprilysin inhibition and RAAS blockade. In a 7-day valsartan- controlled study in patients with reduced ejection fraction (HFrEF), administration of sacubitril/valsartan resulted in an initial increase in natriuresis, increased urine cGMP, and decreased plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) compared to valsartan. In a 21-day study in HFrEF patients, sacubitril/valsartan significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1 compared to baseline.</p><p>The AT1-receptor was also blocked as evidenced by increased plasma renin activity and plasma renin concentrations. In the PARADIGM-HF study, sacubitril/valsartan decreased plasma NT- proBNP and increased plasma BNP and urine cGMP compared with enalapril.</p><p>BNP is not a suitable biomarker of heart failure in patients treated with sacubitril/valsartan because BNP is a neprilysin substrate (see section 4.4). NT-proBNP is not a neprilysin substrate and is therefore a more suitable biomarker.</p><p>In a thorough QTc clinical study in healthy male subjects, single doses of sacubitril/valsartan 194 mg sacubitril/206 mg valsartan and 583 mg sacubitril/617 mg valsartan had no effect on cardiac repolarisation.</p><p>Neprilysin is one of multiple enzymes involved in the clearance of amyloid-&beta; (A&beta;) from the brain and cerebrospinal fluid (CSF). Administration of sacubitril/valsartan 194 mg sacubitril/206 mg valsartan once daily for two weeks to healthy subjects was associated with an increase in CSF A&beta;1-38 compared to placebo; there were no changes in concentrations of CSF A&beta;1- 40 and 1-42. The clinical relevance of this finding is not known (see section 5.3).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths are in some publications referred to as 50, 100 or 200 mg.</p><p><em>PARADIGM-HF</em></p><p>PARADIGM-HF , the pivotal phase 3 study, was a multinational, randomised, double-blind study of 8,442 patients comparing sacubitril/valsartan to enalapril, both given to adult patients with chronic heart failure, NYHA class II-IV and reduced ejection fraction (left ventricular ejection fraction [LVEF] &le;40%, amended later to &le;35%) in addition to other heart failure therapy. The primary endpoint was the composite of cardiovascular (CV) death or hospitalisation for heart failure (HF). Patients with SBP &lt;100 mmHg, severe renal impairment (eGFR &lt;30 ml/min/1.73 m<sup>2</sup>) and severe hepatic impairment were excluded at screening and therefore not prospectively studied.</p><p>Prior to study participation, patients were well treated with standard of care therapy which included ACE inhibitors/ARBs (&gt;99%), beta blockers (94%), mineralocorticoid antagonists (58%) and diuretics (82%). The median follow-up duration was 27 months and patients were treated for up to</p><p>4.3 years.</p><p>Patients were required to discontinue their existing ACE inhibitor or ARB therapy and enter a sequential single-blind run-in period during which they received treatment with enalapril 10 mg twice daily, followed by single-blind treatment with sacubitril/valsartan 100 mg twice daily, increasing to 200 mg twice daily (see section 4.8 for discontinuations during this period). They were then randomised to the double-blind period of the study, during which they received either sacubitril/valsartan 200 mg or enalapril 10 mg twice daily [sacubitril/valsartan (n=4,209); enalapril (n=4,233)].</p><p>The mean age of the population studied was 64 years of age and 19% were 75 years of age or older. At randomisation, 70% of patients were NYHA class II, 24% were class III and 0.7% were class IV. The mean LVEF was 29% and there were 963 (11.4%) patients with a baseline LVEF &gt;35% and</p><p>&le;40%.</p><p>In the sacubitril/valsartan group, 76% of patients remained on the target dose of 200 mg twice daily at the end of the study (mean daily dose of 375 mg). In the enalapril group, 75% of patients remained on the target dose of 10 mg twice daily at the end of the study (mean daily dose of 18.9 mg).</p><p>&nbsp;</p><p>Sacubitril/valsartan was superior to enalapril, reducing the risk of cardiovascular death or heart failure hospitalisations to 21.8% compared to 26.5% for enalapril treated patients. The absolute risk reductions were 4.7% for the composite of the CV death or HF hospitalisation, 3.1% for CV death alone, and 2.8% for first HF hospitalisation alone. The relative risk reduction was 20% versus enalapril (see Table 2). This effect was observed early and was sustained throughout the duration of the study (see Figure 1).</p><p>Both components contributed to the risk reduction. Sudden death accounted for 45% of cardiovascular deaths and was reduced by 20% in sacubitril/valsartan -treated patients compared to enalapril-treated patients (HR 0.80, p=0.0082). Pump failure accounted for 26% of cardiovascular deaths and was reduced by 21% in sacubitril/valsartan -treated patients compared to enalapril-treated patients (HR 0.79, p=0.0338).</p><p>This risk reduction was consistently observed across subgroups including: gender, age, race, geography, NYHA class (II/III), ejection fraction, renal function, history of diabetes or hypertension, prior heart failure therapy, and atrial fibrillation.</p><p>Sacubitril/valsartan improved survival with a significant reduction in all-cause mortality of 2.8% (sacubitril/valsartan , 17%, enalapril, 19.8%). The relative risk reduction was 16% compared with enalapril (see Table 2).</p><p><strong>Table 2 Treatment effect for the primary composite endpoint, its components and all-cause mortality over a median follow-up of 27 months</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong>Sacubitril/ valsartan </strong></p><p><strong>N=4187<sup>♯</sup> n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Enalapril N=4212♯ </strong><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Hazard ratio (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Relative </strong><strong>risk </strong><strong>reduction</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p><p><strong>***</strong></p></td></tr><tr><td style="vertical-align:top"><p>Primary composite endpoint of CV death and heart failure</p><p>hospitalisations*</p></td><td style="vertical-align:top"><p>914 (21.83)</p></td><td style="vertical-align:top"><p>1117 (26.52)</p></td><td style="vertical-align:top"><p>0.80 (0.73, 0.87)</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>0.0000002</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Individual components of the primary composite endpoint</strong></p></td></tr><tr><td style="vertical-align:top"><p>CV death**</p></td><td style="vertical-align:top"><p>558 (13.33)</p></td><td style="vertical-align:top"><p>693 (16.45)</p></td><td style="vertical-align:top"><p>0.80 (0.71, 0.89)</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>0.00004</p></td></tr><tr><td style="vertical-align:top"><p>First heart failure</p><p>hospitalisation</p></td><td style="vertical-align:top"><p>537 (12.83)</p></td><td style="vertical-align:top"><p>658 (15.62)</p></td><td style="vertical-align:top"><p>0.79 (0.71, 0.89)</p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>0.00004</p></td></tr><tr><td style="vertical-align:top"><p><strong>Secondary endpoint</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>All-cause mortality</p></td><td style="vertical-align:top"><p>711 (16.98)</p></td><td style="vertical-align:top"><p>835 (19.82)</p></td><td style="vertical-align:top"><p>0.84 (0.76, 0.93)</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>0.0005</p></td></tr></tbody></table><p>&nbsp;</p><p>*The primary endpoint was defined as the time to first event of CV death or hospitalisation for HF.</p><p>**CV death includes all patients who died up to the cut-off date irrespective of previous hospitalisation.</p><p>***One-sided p-value</p><p>♯ Full analysis set</p><p><strong>Figure 1 Kaplan-Meier curves for the primary composite endpoint and the CV death component</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="600" height="199" vspace="0" hspace="0" border="0" style="width:600px;height:199px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p><em>TITRATION</em></p><p>TITRATION was a 12-week safety and tolerability study in 538 patients with chronic heart failure (NYHA class II&ndash;IV) and systolic dysfunction (left ventricular ejection fraction &le;35%) na&iuml;ve to ACE inhibitor or ARB therapy or on varying doses of ACE inhibitors or ARBs prior to study entry.</p><p>Patients received a starting dose of sacubitril/valsartan of 50 mg twice daily and were up-titrated to 100 mg twice daily, then to the target dose of 200 mg twice daily, with either a 3-week or a 6-week regimen.</p><p>More patients who were na&iuml;ve to previous ACE inhibitor or ARB therapy or on low-dose therapy (equivalent to &lt;10 mg enalapril/day) were able to achieve and sacubitril/valsartan 200 mg when up-titrated over 6 weeks (84.8%) versus 3 weeks (73.6%). Overall, 76% of patients achieved and maintained the target dose of sacubitril/valsartan 200 mg twice daily without any dose interruption or down-titration over 12 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The valsartan contained within sacubitril/valsartan is more bioavailable than the valsartan in other marketed tablet formulations; 26 mg, 51 mg, and 103 mg of valsartan in sacubitril/valsartan is equivalent to 40 mg, 80 mg and 160 mg of valsartan in other marketed tablet formulations, respectively.</p><p><u>Absorption</u></p><p>Following oral administration, sacubitril/valsartan dissociates into valsartan and the prodrug sacubitril. Sacubitril is further metabolised to the active metabolite LBQ657. These reach peak plasma concentrations in 2 hours, 1 hour, and 2 hours, respectively. The oral absolute bioavailability of sacubitril and valsartan is estimated to be more than 60% and 23%, respectively. Following twice daily dosing of sacubitril/valsartan , steady-state levels of sacubitril, LBQ657 and valsartan are reached in three days. At steady state, sacubitril and valsartan do not accumulate significantly, while LBQ657 accumulates 1.6-fold. Administration with food has no clinically significant impact on the systemic exposures of sacubitril, LBQ657 and valsartan.</p><p>Sacubitril/valsartan can be administered with or without food.</p><p>&nbsp;<u>Distribution</u></p><p>Sacubitril, LBQ657 and valsartan are highly bound to plasma proteins (94-97%). Based on the comparison of plasma and CSF exposures, LBQ657 crosses the blood brain barrier to a limited extent (0.28%). The average apparent volume of distribution of valsartan and sacubitril were 75 litres to 103 litres, respectively.</p><p><u>Biotransformation</u></p><p>Sacubitril is readily converted to LBQ657 by carboxylesterases 1b and 1c; LBQ657 is not further metabolised to a significant extent. Valsartan is minimally metabolised, as only about 20% of the dose is recovered as metabolites. A hydroxyl metabolite of valsartan has been identified in plasma at low concentrations (&lt;10%). Since CYP450-enzyme-mediated metabolism of sacubitril and valsartan is minimal, co-administration with medicinal products that impact CYP450 enzymes is not expected to impact the pharmacokinetics.</p><p><u>Elimination</u></p><p>Following oral administration, 52-68% of sacubitril (primarily as LBQ657) and ~13% of valsartan and its metabolites are excreted in urine; 37-48% of sacubitril (primarily as LBQ657) and 86% of valsartan and its metabolites are excreted in faeces.</p><p>Sacubitril, LBQ657 and valsartan are eliminated from plasma with a mean elimination half-life (T<sub>&frac12;</sub>) of approximately 1.43 hours, 11.48 hours, and 9.90 hours, respectively.</p><p><u>Linearity/non-linearity</u></p><p>The pharmacokinetics of sacubitril, LBQ657 and valsartan were approximately linear over an sacubitril/valsartan dose range of 24 mg sacubitril/26 mg valsartan to 97 mg sacubitril/103 mg valsartan.</p><p><u>Special populations</u></p><p><em>Elderly patients</em></p><p>LBQ657 and valsartan exposure are increased in subjects over 65 years of age by 42% and 30%, respectively, compared to younger subjects.</p><p><em>Impaired renal function</em></p><p>A correlation was observed between renal function and systemic exposure to LBQ657 in patients with mild to severe renal impairment. The exposure of LBQ657 in patients with moderate (30 ml/min/1.73 m<sup>2</sup> &le; eGFR &lt;60 ml/min/1.73 m<sup>2</sup>) and severe renal impairment (15 ml/min/1.73 m<sup>2</sup> &le; eGFR &lt;30 ml/min/1.73 m<sup>2</sup>) was 1.4-fold and 2.2-fold higher compared to patients with mild renal impairment (60 ml/min/1.73 m<sup>2</sup> &le; eGFR &lt;90 ml/min/1.73 m<sup>2</sup>), the largest group of</p><p>patients enrolled in PARADIGM-HF). The exposure of valsartan was similar in patients with moderate and severe renal impairment compared to patients with mild renal impairment. No studies have been performed in patients undergoing dialysis. However, LBQ657 and valsartan are highly bound to plasma protein and therefore unlikely to be effectively removed by dialysis.</p><p><em>Impaired hepatic function</em></p><p>In patients with mild to moderate hepatic impairment, the exposures of sacubitril increased by 1.5- and 3.4- fold, LBQ657 increased by 1.5- and 1.9-fold, and valsartan increased by 1.2-fold and 2.1- fold, respectively, compared to matching healthy subjects. However, in patients with mild to moderate hepatic impairment, the exposures of free concentrations of LBQ657 increased by 1.47-and 3.08-fold, respectively, and the exposures of free concentrations of valsartan increased by 1.09-fold and 2.20-fold, respectively, compared to matching healthy subjects. Sacubitril/valsartan has not been studied in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Effect of gender</em></p><p>The pharmacokinetics of sacubitril/valsartan (sacubitril, LBQ657 and valsartan) are similar between male and female subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data (including studies with sacubitril and valsartan components and/or sacubitril/valsartan) reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and fertility.</p><p><u>Fertility, reproduction and development</u></p><p>Sacubitril/Valsartan treatment during organogenesis resulted in increased embryofoetal lethality in rats at doses &ge;49 mg sacubitril/51 mg valsartan/kg/day (&le;0.72-fold the maximum recommended human dose [MRHD] on the basis of AUC) and rabbits at doses &ge;4.9 mg sacubitril/5.1 mg valsartan/kg/day (2-fold and 0.03-fold the MRHD on the basis of valsartan and LBQ657 AUC, respectively). It is teratogenic based on a low incidence of foetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at a sacubitril/valsartan dose of &ge;4.9 mg sacubitril/5.1 mg valsartan/kg/day. Cardiovascular abnormalities (mainly cardiomegaly) were observed in rabbit foetuses at a maternally non-toxic dose (1.46 mg sacubitril/1.54 mg valsartan/kg/day). A slight increase in two foetal skeletal variations (misshapen sternebra, sternebra bipartite ossification) was observed in rabbits at a sacubitril/valsartan dose of 4.9 mg sacubitril/5.1 mg valsartan/kg/day. The adverse embryofoetal effects of sacubitril/valsartan are attributed to the angiotensin receptor antagonist activity (see section 4.6).</p><p>Sacubitril treatment during organogenesis resulted in embryo-foetal lethality and embryo-foetal toxicity (decreased foetal body weights and skeletal malformations) in rabbits at doses associated with maternal toxicity (500 mg/kg/day; 5.7-fold&nbsp;the MRHD on the basis of LBQ657 AUC). A slight generalised delay in ossification was observed at doses of &gt;50 mg/kg/day. This finding is not considered adverse. No evidence of embryo-foetal toxicity or teratogenicity was observed&nbsp;in rats treated with sacubitril. The embryo-foetal no-observed adverse effect level (NOAEL) for sacubitril was at least 750 mg/kg/day in rats and 200 mg/kg/day in rabbits (2.2-fold the MRHD on the basis of LBQ657 AUC).</p><p>Pre- and postnatal development studies in rats conducted with sacubitril at high doses up to 750 mg/kg/day (2.2-fold the MRHD on the basis of AUC) and valsartan at doses up to 600 mg/kg/day (0.86-fold the MRHD on the basis of AUC) indicate that treatment with sacubitril/valsartan during organogenesis, gestation and lactation may affect pup development and survival.</p><p>&nbsp;</p><p><u>Other preclinical findings</u></p><p><em>Sacubitril/Valsartan</em></p><p>The effects of sacubitril/valsartan on amyloid-&beta; concentrations in CSF and brain tissue were assessed in young (2-4 years old) cynomolgus monkeys treated with sacubitril/valsartan (24 mg sacubitril/26 mg valsartan/kg/day) for two weeks. In this study CSF A&beta; clearance in cynomolgus monkeys was reduced, increasing CSF A&beta;1-40, 1-42 and 1-38 levels; there was no corresponding increase in A&beta; levels in the brain. Increases in CSF A&beta;1-40 and 1-42 were not observed in a two-week healthy volunteer study in humans (see section 5.1). Additionally, in a toxicology study in cynomolgus monkeys treated with sacubitril/valsartan at 146 mg sacubitril/154 mg valsartan/kg/day for 39 weeks, there was no evidence for the presence of amyloid plaques in the brain. Amyloid content was not, however, measured quantitatively in this study.</p><p><em>Sacubitril</em></p><p>In juvenile rats treated with sacubitril (postnatal days 7 to 70), there was a reduction in age-related bone mass development and bone elongation. A study in adult rats showed only a minimal transient inhibitory effect on bone mineral density but not on any other parameters relevant for bone growth, suggesting no relevant effect of sacubitril on bone in adult patient populations under normal conditions. However, a mild transient interference of sacubitril with the early phase of fracture healing in adults cannot be excluded.</p><p><em>Valsartan</em></p><p>In juvenile rats treated with valsartan (postnatal days 7 to 70), doses as low as 1 mg/kg/day produced persistent irreversible kidney changes consisting of tubular nephropathy (sometimes accompanied by tubular epithelial necrosis) and pelvic dilatation. These kidney changes represent an expected exaggerated pharmacological effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 blockers; such effects are observed if rats are treated during the first 13 days of life. This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp; </strong><strong><u>Tablet core</u></strong></p><p>Microcrystalline cellulose (PH 112), Crospovidone, Croscarmellose sodium,Colloidal silicon Dioxide, Talc, Magnesium stearate, Purified water.</p><p><strong><u>Coating:</u></strong></p><p><em>Saventi 24</em><em> </em><em>mg/</em><em> </em><em>26</em><em> </em><em>mg film</em><em>-coated tablets</em><em>:</em><em> </em>Opadry Purple 03F500057</p><p><em>Saventi</em><em> 49 </em><em>mg/51</em><em> </em><em>mg </em><em>&nbsp;film-coated tablets</em><em>:</em><em> </em>Opadry Yellow 03F520058</p><p><em>Saventi 97</em><em> </em><em>mg/103</em><em> </em><em>mg film-coated tablets: </em>Opadry Pink 03F540048</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>60&#39;s, 180&#39;s HDPE container pack.</p><p>10&#39;s Blister Pack</p><p><strong><em>Note: </em></strong>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC) 
King Fahad Road – King Fahad District, Building no. 7639 
P.O. Box 12262 Riyadh, Saudi Arabia 
Tel: +966-11-920001432 
Fax: +966-11-4668195 
Email: info@sudairpharma.com  
Manufacturer: 
MSN Laboratories Private Limited
Formulations Division, Unit-II,
Survey Nos. 1277, 1319 to 1324,
Nandigama (Village & Mandal),
Rangareddy District, Telangana- 509 228, India
Tel: +91-40-30449200
Fax: +91-40-30449211

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>